LYELL IMMUNOPHARMA INC. - COMMON STOCK

Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025

01 مايو 2025 09:00:08 بحسب Nasdaq GlobeNewswire

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma

15 أبريل 2025 09:00:00 بحسب Nasdaq GlobeNewswire

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024

11 مارس 2025 16:05:00 بحسب Nasdaq GlobeNewswire

Lyell Immunopharma Announces Participation in Upcoming Investor Conferences

18 فبراير 2025 16:05:00 بحسب Nasdaq GlobeNewswire

Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference

09 يناير 2025 09:00:00 بحسب Nasdaq GlobeNewswire

Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting

09 ديسمبر 2024 21:00:00 بحسب Nasdaq GlobeNewswire

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024

07 نوفمبر 2024 16:05:03 بحسب Nasdaq GlobeNewswire

Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

05 نوفمبر 2024 09:30:00 بحسب Nasdaq GlobeNewswire

Lyell Immunopharma Completes Acquisition of ImmPACT Bio

31 أكتوبر 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies

24 أكتوبر 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

04 أكتوبر 2024 09:00:00 بحسب Nasdaq GlobeNewswire

Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day

24 سبتمبر 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Lyell Immunopharma Announces Participation in September Investor Conferences

28 أغسطس 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024

07 أغسطس 2024 16:05:01 بحسب Nasdaq GlobeNewswire

Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology

26 يونيو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

03 يونيو 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Lyell Immunopharma to Participate in BofA Securities Health Care Conference

07 مايو 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024

06 مايو 2024 08:00:01 بحسب Nasdaq GlobeNewswire

Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting

05 مارس 2024 16:30:00 بحسب Nasdaq GlobeNewswire

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023

28 فبراير 2024 16:05:00 بحسب Nasdaq GlobeNewswire